Marshall Wace North America Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$113M |
| 2 |
BERY
Berry Global Group, Inc.
BERY
|
+$106M |
| 3 |
Merck
MRK
|
+$95.9M |
| 4 |
Baidu
BIDU
|
+$85.8M |
| 5 |
IQVIA
IQV
|
+$83.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$229M |
| 2 |
Las Vegas Sands
LVS
|
+$150M |
| 3 |
Alibaba
BABA
|
+$131M |
| 4 |
Citigroup
C
|
+$130M |
| 5 |
Micron Technology
MU
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.85% |
| 2 | Technology | 15.39% |
| 3 | Consumer Discretionary | 13.45% |
| 4 | Industrials | 10.48% |
| 5 | Financials | 9.65% |
Similar funds
Marshall Wace North America's Q2 2018 Portfolio in Review
As of Q2 2018, Marshall Wace North America held 1,947 positions worth $17.7B, down 11% from $20B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Marshall Wace North America withdrew a net $3.05B in Q2 2018, closing 606 positions and reducing 444 holdings. Its most notable exit was Time Warner Inc, an estimated $63.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Marshall Wace North America opened a new position in IQVIA worth $83.1M.
- Marshall Wace North America's largest Q2 2018 buy was IQVIA: 832,159 shares worth $83.1M.
- Marshall Wace North America added most to Vertex Pharmaceuticals in Q2 2018, an estimated $113M increase.
- Marshall Wace North America's biggest Q2 2018 reduction was Johnson & Johnson, cutting an estimated $229M.
- Marshall Wace North America fully exited Time Warner Inc in Q2 2018, selling an estimated $63.3M.
- Marshall Wace North America's ten largest holdings make up 16% of its $17.7B portfolio in Q2 2018.
- Marshall Wace North America opened 557 new positions and closed 606 in Q2 2018.
- Marshall Wace North America's portfolio value fell 11% quarter-over-quarter to $17.7B.
Based on Marshall Wace North America's 13F filing for Q2 2018, filed 14 Aug 2018.